热毒宁与利巴韦林联合应用治疗小儿手足口病的临床优势分析

摘要

Objective:To analyze the clinical advantages of reduning combined with ribavirin in the treatment of children with hand-foot-mouth disease.Method:The clinical data of 56 children with hand foot and mouth disease in the hospital were retrospectively analyzed. They were divided into the treatment group and the control group,28 cases in each group.The control group was treated with ribavirin,and the treatment group was taken with Reduning on the basis of ribavirin.The clinical efficacy and the incidence of adverse reactions of the two groups were compared.Result:After treatment, the total effective rate of treatment group(92.86%)was significantly higher than the control group(82.14%,P<0.05).The cure rate was significant difference between treatment group(42.85%)and control group(32.14%,P<0.05).And the incidence rate of adverse reaction was significant difference between the two groups(P<0.05),which in the treatment group was 7.14%and in the control group was 14.28%.Conclusion:Reduning combined with ribavirin in the treatment of children with hand foot and mouth disease is with high safety,and the clinical curative effect is significant.%目的：分析热毒宁联合利巴韦林治疗小儿手足口病的临床优势。方法：回顾性分析本院收治的56例手足口病患儿的临床资料，根据治疗方法不同分为治疗组和对照组各28例。其中对照组患儿单用利巴韦林治疗，治疗组患儿在对照组治疗的基础上加用热毒宁治疗，比较两组患儿的临床疗效和不良反应发生情况。结果：治疗组的总有效率为92.86%，明显高于对照组的总有效率82.14%；治疗组的治愈率42.85%明显高于对照组的32.14%，差异均有统计学意义（P<0.05）。治疗组不良反应发生率7.14%明显低于对照组的14.28%，差异有统计学意义（P<0.05）。结论：热毒宁联合利巴韦林治疗小儿手足口病，安全性高，临床疗效显著。